Compare Repligen Corporation Common Stock (RGEN) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs iShares Silver Trust — how do they compare? Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B), while iShares Silver Trust trades at $51.16 (market cap $28.90B). The key difference: iShares Silver Trust is far larger — about 2.6× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and iShares Silver Trust for 90 Days on average.
| RGEN | SLV | |
|---|---|---|
Market Cap | $11.31B | $28.90B |
Volume | 1,216,919 | 36,248,796 |
Sector | Health | — |
52-Week High | $194.57 | $105.57 |
52-Week Low | $102.87 | $42.40 |
Typical Hold Time | 0 Days | 90 Days |
Enterprise Value | $11.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SLV (iShares Silver Trust) trades at $53.49, down 1.58% amid bearish technical signals with 17 sell indicators versus 1 buy. The ETF shows minimal operational activity with $0 revenue but generated $2.17M net income in 2024, supported by $13.41B in total assets against negligible liabilities. Recent news highlights silver's volatility tied to Fed policy and Treasury yields, with prices pressured by hawkish rate expectations.
Outlook remains cautious as technical weakness and macroeconomic headwinds dominate. Silver's dual role as monetary and industrial metal exposes SLV to Fed policy shifts and dollar strength, though long-term demand catalysts like central bank buying offer potential upside. Risks include sustained rate hikes and industrial demand fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
